Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Importance Limited treatment responses in schizophrenia prompted the testing of combining
an antipsychotic drug treatment with a second psychotropic medication. A comprehensive …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals
diagnosed with schizophrenia. The identification and management of TRS in clinical …

Importance In treatment-resistant schizophrenia, clozapine is considered the standard
treatment. However, clozapine use has restrictions owing to its many adverse effects …

Negative symptoms in schizophrenia may be classified as primary or secondary. Primary
negative symptoms are thought to be intrinsic to schizophrenia, while secondary negative …

Severe psychiatric disorders such as schizophrenia are related to cognitive and negative
symptoms, which often are resistant to current treatment approaches. The glutamatergic …

Background Evidence for the management of inadequate clinical response to clozapine in
treatment-resistant schizophrenia is sparse. Accordingly, an international initiative was …

Negative symptoms (such as amotivation and diminished expression) associated with
schizophrenia are a major health concern. Adequate treatment would mean important …

Clozapine is a highly effective antipsychotic medication, which provides a range of
significant benefits for patients with schizophrenia, and is the standard of care for treatment …